Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01686-18. doi: 10.1128/AAC.01686-18. Print 2018 Dec.

Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.

Author information

1
PHPT/IRD, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand tim.cressey@phpt.org.
2
Department of Immunology & Infectious Diseases, Boston, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
3
Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
4
Center for Biostatistics in AIDS Research (CBAR), Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
5
Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.
6
Banglamung Hospital, Chonburi, Thailand.
7
Nopparat Rajathanee Hospital, Bangkok, Thailand.
8
Lampang Hospital, Lampang, Thailand.
9
Khon Kaen Hospital, Khon Kaen, Thailand.
10
Chiang Kham Hospital, Phayao, Thailand.
11
Phayao Provincial Hospital, Phayao, Thailand.
12
PHPT/IRD, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
13
Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
14
Institut de Recherche pour le Développement (IRD), Unité Mixte Internationale 174-PHPT, Chiang Mai, Thailand.
15
Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
16
Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.

Abstract

We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC0-24 was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.

KEYWORDS:

hepatitis B virus; pharmacokinetics; pregnancy; tenofovir

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center